# Pizarra — PT-pseudo_d7d26761c714 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_d7d26761c714
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 7.7 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.03 ng/mL/yr
  - Prior PSA: 4.6 ng/mL
  - Prostate volume: 73.0 mL
  - Months since last PSA: 1
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.6079056 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension
  - Problem list / PMHx: Hypertension
  - Current medication: valsartan, metoprolol
  - Allergies: NKA
  - Additional notes: PSA 7.7 ng/mL. PI-RADS 3. PSAD 0.11. Prostate volume 73 mL. csPCa 0.61.

Vitals: weight 86 kg, height 177 cm, BMI 27.5, BP 120/82 mmHg, HR 80 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested due to prior histological confirmation of malignancy and a recent PSA rise to 7.7 ng/mL.

History: At 64 years of age, this mechanical engineer entered surveillance protocols after a positive biopsy established ISUP Grade Group 1 carcinoma. Residing on an operational agricultural property alongside his spouse, his daily routine entails early hours and intermittent manual tasks, yet he characterizes his general mobility as largely sedentary with sporadic strolls. Lower urinary tract complaints are entirely absent, reflected by an IPSS score of 1. He explicitly denies haematuria, pelvic discomfort, or osseous pain. Cardiovascular parameters remain stable under valsartan and metoprolol therapy, a combination maintained for years. A minor knee arthroscopy performed in his late forties constitutes his sole surgical history, alongside a mild visual deficit necessitating large-print reading materials. Alcohol intake averages four units per week, and documented allergies remain absent. His long-standing companion acts as his designated next of kin. He abstains from tobacco entirely.

Physical examination: DRE — glandular assessment: symmetrically enlarged, uniformly smooth with firm consistency, devoid of discrete nodules or contour irregularities. General inspection: well-nourished adult, appearing comfortable without acute distress. Auscultation confirms clear pulmonary fields and a regular cardiac rhythm measuring 80 beats per minute. Vascular pressure registers 120/82 mmHg. Lower extremities show no pitting oedema, and lymphatic chains remain non-palpable.

Patient info: mechanical engineer; Married; Lives on a working farm with partner.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Sedentary lifestyle, occasional walking; IPSS score: 1/35 (mild LUTS).


Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.34 +/- 0.15   (95% CI 0.04-0.65)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.15  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 0.93 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'supports': p +/- dp does not cross 0.5 but p +/- 1.96*dp does. A direction, not a conclusion; a weighted vote. Measured accuracy in this tier on the labelled cohort: 0.8 over 20 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and management agreement?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy decision. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed structured data (PSA, PI-RADS, volume, prior biopsy status, etc.). It could not weigh the context provided by the mpMRI prose, such as whether the lesion size/zone has changed compared to a previous study, or the specific trajectory of the PSA beyond the headline value. It also did not account for the guideline's emphasis on the need to check if the prior grade is documented or if the lesion changed against a previous MRI.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.34 +/- 0.15. This suggestion could be wrong because the guideline states the decision must come from retrieved documents, and the prior failed to account for the need to check if the prior grade is documented or if the lesion changed against a previous MRI. Furthermore, the guideline notes that a stable MRI (PRECISE 1-3) combined with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Discrete abnormality localized to the left mid-gland peripheral compartment, assigned PI-RADS 3. The report notes the gland volume is 73.0 mL and the csPCa probability is 0.6079056.

get_psa_trend
PSA trend: PSA values were 5.3 ng/mL (Dec 2022), 5.1 ng/mL (Dec 2023), and 7.7 ng/mL (Jan 2025). This shows a rising trend in PSA over time.

get_previous_notes
Previous notes: The prior biopsy established ISUP Grade Group 1 carcinoma. The patient entered surveillance protocols after the initial elevation. The last documented consultation was May 2024, where imaging and pathology were completed. No specific re-biopsy protocol or treatment plan is explicitly detailed in the retrieved notes.

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend shows a clear rising trajectory (5.3 -> 5.1 -> 7.7 ng/mL).
- The prior biopsy established ISUP Grade Group 1 carcinoma, and the current PSA is elevated (7.7 ng/mL).

AGAINST sampling this patient now:
- The mpMRI shows a PI-RADS 3 lesion, which is equivocal, and the report does not explicitly state if the lesion size/zone has changed against a previous study.

WHERE THIS LEANS
The rising PSA trend and the established prior diagnosis suggest a need for further characterization, despite the equivocal PI-RADS 3 score.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

REOPENING THE BLACKBOARD (round 2 of 2).

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved evidence (rising PSA trend and established prior diagnosis) leans towards biopsy, which aligns with the LLM-2-EVIDENCE finding. The record is sufficient to proceed to the final decision by the Chair.

WHY: the agenda WAS fulfilled and the participants still disagree, so this is a disagreement about INTERPRETATION, not about missing data. DO NOT OPEN ANY FURTHER DOCUMENT - there is nothing left that would settle it, and an extra reveal costs precision for nothing. Instead, go back to what is already on the board and answer one question: which of the two positions is supported by a retrieved finding, and which one is supported only by the visible panel that every participant could already see? Name that finding.

---

# Ronda 2

## [9] GAPS AND DOUBTS (round 2)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed structured data (PSA, PI-RADS, volume, prior biopsy status, etc.). It could not weigh the context provided by the mpMRI prose, such as whether the lesion size/zone has changed compared to a previous study, or the specific trajectory of the PSA beyond the headline value. It also did not account for the guideline's emphasis on the need to check if the prior grade is documented or if the lesion changed against a previous MRI.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a probability of 0.34 +/- 0.15. This suggestion could be wrong because the guideline states the decision must come from retrieved documents, and the prior failed to account for the need to check if the prior grade is documented or if the lesion changed against a previous MRI. Furthermore, the guideline notes that a stable MRI (PRECISE 1-3) combined with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?
previous_notes - What was the prior grade, surveillance pathway, and management agreement?

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [10] EVIDENCE REPORT (round 2)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: Discrete abnormality localized to the left mid-gland peripheral compartment, assigned PI-RADS 3. The report notes the gland volume is 73.0 mL and the csPCa probability is 0.6079056.

get_psa_trend
PSA trend: PSA values were 5.3 ng/mL (Dec 2022), 5.1 ng/mL (Dec 2023), and 7.7 ng/mL (Jan 2025). This shows a rising trend in PSA over time.

get_previous_notes
Previous notes: The prior biopsy established ISUP Grade Group 1 carcinoma. The patient entered surveillance protocols after the initial elevation. The last documented consultation was May 2024, where imaging and pathology were completed. No specific re-biopsy protocol or treatment plan is explicitly detailed in the retrieved notes.

NOT RETRIEVED
laboratory_results
The full laboratory panel was not retrieved because the moderator's agenda did not explicitly require it, and no immediate question arose from the retrieved documents.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA trend shows a clear rising trajectory (5.3 -> 5.1 -> 7.7 ng/mL).
- The prior biopsy established ISUP Grade Group 1 carcinoma, and the current PSA is elevated (7.7 ng/mL).

AGAINST sampling this patient now:
- The mpMRI shows a PI-RADS 3 lesion, which is equivocal, and the report does not explicitly state if the lesion size/zone has changed against a previous study.

WHERE THIS LEANS
The rising PSA trend and the established prior diagnosis suggest a need for further characterization, despite the equivocal PI-RADS 3 score.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [11] CLOSING CHECK (round 2)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=no, protocol=abstains, evidence=yes.
Consensus: no — split {'no': 1, 'yes': 1}.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The agenda was fulfilled, and the evidence leans towards biopsy due to the rising PSA trend and established prior diagnosis, despite the equivocal PI-RADS 3 score. The remaining uncertainty lies in the specific comparison of the current MRI findings to prior imaging.

The chair decides on the record as it stands.

## [12] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: NO BIOPSY   (confidence: borderline)

The statistical prior suggested no biopsy (p=0.34), which was overturned by the retrieved evidence showing a clear rising PSA trend (5.3 -> 7.7 ng/mL) and the established prior diagnosis of ISUP Grade Group 1 carcinoma. The guideline criterion abstained because the panel did not settle the case, leaving the decision to the retrieved documents. Since no retrieved document explicitly stated a reason to proceed with biopsy (like an undocumented grade or changed lesion), the decision defaults to deferral, despite the rising PSA.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
